Skip to main content

SkylineDx, Mayo Clinic to Develop Diagnostic Tests for Melanoma

NEW YORK (GenomeWeb) – SkylineDx said today that it is collaborating with the Mayo Clinic to develop new diagnostic tests to improve clinical decision-making for melanoma patients.

The company said that it is lending its expertise in informatics to help optimize and further develop an algorithm — originally discovered and developed by Mayo Clinic dermatologist Alexander Meves — that identifies risk factors associated with metastasis.

Meves and his colleagues originally published their findings in the Journal of Clinical Oncology in 2015, and plan to present new data at the 2018 American Academy of Dermatology Annual Meeting in San Diego, California this February, Skyline said. If validated, the resulting test would be designed to help physicians prescribe the appropriate treatment interventions based on a patient's risk of disease progression.

Apart from this new collaboration, Skyline has largely been focused on developing tests to stratify and predict optimal treatments for patients with multiple myeloma.

As such, company officials called the agreement with the Mayo Clinic a significant achievement, which it believes will enable it to extend its product offering.

Commercialization and other financial terms of the collaboration were not disclosed.